Search
Asha Jonathan Marianne Bowen Carapetis AM Mullane BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) Head, Healthy Skin
Healthy skin is important for maintaining overall health and wellbeing. Some skin infections, if untreated, can lead to serious downstream health complications such as heart disease, kidney disease, or sepsis.
The aim of this project is to conduct a situational analysis of the skin health services and activities currently available for managing skin infections within the Kimberley.
The skin is home to an array of bacteria, fungi and viruses, which together make up the skin microbiome. We explore how the skin microbiome can contribute to healthy skin.
Dr Anita Asha Campbell Bowen MBBS, DCH, PG DipPID, FRACP, PhD BA MBBS DCH FRACP PhD GAICD FAHMS OAM Infectious Diseases Physician; Raine Clinician
Dr Amgarth-Duff is an early career Post-doctoral Senior Research Offer in the Healthy Skin & ARF prevention team.
Although Streptococcus pyogenes (Strep A) is the sixth-most common infectious disease globally, its transmission within the household remains an understudied driver of infection. We undertook a systematic review to better understand the transmission of Strep A among people within the home, while highlighting opportunities for prevention.
Although Streptococcus pyogenes (Strep A) is the sixth-most common infectious disease globally, its transmission within the household remains an understudied driver of infection. We undertook a systematic review to better understand the transmission of Strep A among people within the home, while highlighting opportunities for prevention.
Controlled human infection (CHI) models can provide insights into transmission of pathogens such as Streptococcus pyogenes (Strep A). As part of the Controlled Human Infection with Penicillin for Streptococcus pyogenes (CHIPS) trial, we explored the potential for transmission among participants deliberately infected with the Strep A emm75 strain.
Staphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.